White crystalline powder, soluble in organic solvents such as methanol, ethanol, and DMSO, derived from ginseng.
(20S)-Protopanaxatriol acts as an inhibitor in the production of corticosteroids in fasciculata cells. Used in the clinical treatment of heart diseases.
ChEBI: Protopanaxatriol is a tetracyclic triterpenoid sapogenin (isolated from ginseng and notoginseng) that is that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions and in which a double bond has been introduced at the 24-25 position. It has a role as a metabolite. It is a tetracyclic triterpenoid, a sapogenin, a 3beta-hydroxy steroid, a 12beta-hydroxy steroid, a 6alpha-hydroxy steroid and a 3beta-hydroxy-4,4-dimethylsteroid. It derives from a hydride of a dammarane.
A metabolites of ginsenoside, protopanaxatriol (g-PPT), could modulate endothelial cell functions through the glucocorticoid receptor (GR) and oestrogen receptor (ER).
(20S)-Protopanaxatriol (10mg/kg; i.p.; daily for four weeks) synergizes with Gefitinib to inhibit xenograft growth[3].
(20S)-Protopanaxatriol (50-100 mg/kg; p.o.; 25 days; female BALB/c nude mice bearing breast cancer MCF-7 cell) inhibits the growth of MCF-7 breast cancer cells in a nude mice xenograft assay[4].
| Animal Model: | H1975 murine xenograft tumor model |
| Dosage: | 10mg/kg |
| Administration: | I.p.; daily for four weeks |
| Result: | The combined g-PPT and Gefitinib (50 mg/kg/day) treatment clearly reduced p-EGFR and KI67 expression and increased c-Caspase3 expression compared to Gefitinib or g-PPT treatment alone.
|
Antifection | Glucocorticoid receptor | Oestrogen receptor | LXRα
